Stocktoria
UroGen Pharma Ltd. URGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-04
UroGen Pharma Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M |
| R&D expense | $67.1M | $57.1M | $45.6M | $52.9M | $47.6M |
| SG&A expense | $155.1M | $121.2M | $93.3M | $82.8M | $87.5M |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M | -$92.3M |
| Income tax | $78,000 | $2.8M | $3.9M | $1.8M | $1.4M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M | -$110.8M |
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M | -$84.9M |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M | -$85.6M |
| Cash & equivalents | $110.7M | $172.0M | $95.0M | $55.4M | $44.4M |
| Inventory | $16.5M | $9.2M | $5.7M | $4.3M | $4.8M |
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M | $111.3M |
| Shareholders' equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M | $8.4M |
Source: SEC EDGAR filings · CIK 0001668243 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.